2021 American Transplant Congress
Alemtuzumab vs Antithymocyte Globulin Induction in Hepatitis C Viremic Donors to Hepatis C Negative Kidney Transplant Recipients
University of North Carolina Medical Center, Chapel Hill, NC
*Purpose: The optimal induction agent for kidney transplantation of hepatitis C virus nucleic acid test positive donors to negative recipients (HCV NAT D+/R-) is unknown.…2021 American Transplant Congress
Induction in Pancreas Transplantation: T-Cell Depletion vs. Il-2 Receptor Blockade
University of Wisconsin, Madison, WI
*Purpose: There are limited data comparing outcomes with different induction agents in pancreas transplantation. In this study, we compare T-cell depletion to IL-2 receptor (IL2R)…2021 American Transplant Congress
Dual-Agent Induction Therapy for Pancreas Transplantation: A Single-center Experience
*Purpose: The optimal induction strategy in pancreas transplantation has not been elucidated. Available evidence supports use of both basiliximab and lymphocyte depleting agents. Rabbit anti-thymocyte…2021 American Transplant Congress
Induction Immunosuppression Efficacy in Pancreas and Kidney Transplantation in the SARS-CoV-2 Era
University of Minnesota, Minneapolis, MN
*Purpose: Lymphocyte depleting induction is associated with increased risk of infection. Our institution adopted a stratified induction protocol with the intent to decrease risk for…2021 American Transplant Congress
Modification in Immunosuppression Regimens to Safely Perform Kidney Transplants Amid the Covid-19 Pandemic
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: In the USA, there was a 51.1% reduction in kidney transplant (KTx) since March 2020 due to concerns for contraction of COVID-19 in transplant…2021 American Transplant Congress
Covid-19 Severity within One Year of Liver, Pancreas and Kidney Transplantation
Solid Organ Transplant Surgery, University of Minnesota, Minneapolis, MN
*Purpose: The current pandemic has created uncertainty in the severity of COVID-19 in transplant recipients, especially those given lymphocyte depleting therapy within a year prior…2021 American Transplant Congress
Influence of Induction Therapy and Antiretroviral Regimen on Outcomes in HIV Positive Renal Transplant Recipients
*Purpose: Transplantation of HIV+ individuals has become more common over the past decade with increasing data supporting good outcomes. Questions remain regarding the impact of…2021 American Transplant Congress
Basiliximab versus Alemtuzumab: The Association Between Induction Agent and Airway Complications Following Lung Transplantation
1Cardiothoracic Surgery, UPMC, Pittsburgh, PA, 2PUH-Pharmacy, UPMC, Pittsburgh, PA
*Purpose: Controversy still exist regarding the best induction strategy for lung transplantation. At our institution, induction is defined based on donor recipient CMV match. While…2021 American Transplant Congress
Single-Dose Basiliximab Induction Therapy in Low-Immunologic Risk Kidney Transplant Recipients
Pharmacy, Nebraska Medicine, Omaha, NE
*Purpose: The purpose of this study is to examine the outcomes associated with single-dose basiliximab in low-immunologic risk kidney transplant recipients following a revision to…2020 American Transplant Congress
Anti-Thymocyte Globulin versus Interleukin-2 Receptor Antagonist and Deceased-Donor Kidney Transplant Outcomes among Older Recipients
*Purpose: Kidney transplantation (KT) has been growing treatment option for older end-stage renal disease patients. Although lymphocyte-depleting agents are considered to be superior than interleukin-2…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 31
- Next Page »